Mark Yarchoan

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Neoplasms 96%
3. Immunotherapy 85%
4. Immunity 61%
5. Mitogen-Activated Protein Kinase Kinases 57%
6. Tumor Burden 57%
7. T-Lymphocytes 54%
8. Adenocarcinoma 52%
9. Tumor Microenvironment 50%
10. Alzheimer Disease 46%
11. Biliary Tract Neoplasms 45%
12. Nivolumab 41%
13. cabozantinib 41%
14. Pancreatic Neoplasms 39%
15. Biomarkers 38%
16. Therapeutics 36%
17. Ipilimumab 35%
18. Cholangiocarcinoma 35%
19. Fibrolamellar hepatocellular carcinoma 34%
20. Survival 29%
21. Clinical Trials 28%
22. Liver Neoplasms 26%
23. Cancer Vaccines 25%
24. GDC-0973 24%
25. Progression-Free Survival 24%
26. Vaccines 23%
27. Ligands 22%
28. B-Lymphocytes 21%
29. Lymphocyte Count 21%
30. GVAX vaccine 21%
31. Mutation 21%
32. Colitis 20%
33. atezolizumab 19%
34. Colorectal Neoplasms 18%
35. pembrolizumab 18%
36. pramlintide 17%
37. Cell Death 16%
38. Homoharringtonine 16%
39. Granzymes 15%
40. trametinib 15%
41. olaparib 15%
42. Sorafenib 15%
43. Pathology 15%
44. Regulatory B-Lymphocytes 15%
45. Physicians' Practice Patterns 15%
46. pazopanib 14%
47. Turcot syndrome 14%
48. Irinotecan 14%
49. B-Cell Activating Factor 14%